FindTrial
Sign In

Venetoclax (VEN)

DRUG6 trials

Sponsors

Janssen Research & Development, LLC, Technische Universität Dresden, Nanfang Hospital, Southern Medical University

Conditions

AML - Acute Myeloid LeukemiaAcute Myeloid Leukaemia (AML)ConditioningHematopoietic Stem Cell Transplantation (HSCT)Leukemia, Myeloid, AcuteMeasurable Residual Disease (MRD)Myelodysplastic NeoplasmsMyeloid Malignancies

Phase 1

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
Active, not recruitingNCT05453903
Janssen Research & Development, LLCLeukemia, Myeloid, Acute
Start: 2022-10-04End: 2027-03-19Updated: 2026-03-12
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
RecruitingNCT06651229
Janssen Research & Development, LLCLeukemia, Myeloid, Acute, Myelodysplastic Neoplasms
Start: 2025-03-21End: 2028-11-21Target: 155Updated: 2026-04-03

Phase 2

Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment
RecruitingNCT06696183
Technische Universität DresdenAML - Acute Myeloid Leukemia
Start: 2025-04-25End: 2030-04-30Target: 60Updated: 2025-05-29
VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT
Not yet recruitingNCT07052422
Nanfang Hospital, Southern Medical UniversityConditioning, Hematopoietic Stem Cell Transplantation (HSCT), Myeloid Malignancies +1
Start: 2025-07-15End: 2029-12-31Target: 160Updated: 2025-07-04
Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study
Not yet recruitingNCT07264010
Nanfang Hospital, Southern Medical UniversityAcute Myeloid Leukaemia (AML), Measurable Residual Disease (MRD)
Start: 2025-12-01End: 2028-12-30Target: 87Updated: 2025-12-04

Phase 3

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RecruitingNCT06852222
Janssen Research & Development, LLCLeukemia, Myeloid, Acute
Start: 2025-06-04End: 2029-08-15Target: 600Updated: 2026-03-19

Related Papers

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy
Blood2025-11-031 citations
Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)
Blood2025-11-031 citations
Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations
Blood2025-11-031 citations
Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations
Blood2025-11-031 citations
Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with <i>KMT2Ar</i> or <i>NPM1</i> Alterations
Blood2024-11-0520 citations
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in <i>KMT2A</i>- and <i>NPM1</i>-altered leukemias
Blood2024-06-2143 citations
Preclinical Efficacy of the Menin-KMT2A Inhibitor JNJ-75276617 in Combination with Venetoclax and Azacitidine in AML
Blood2023-11-023 citations